Ira Klein, MD, Discusses Quality Measures in Oncology
Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
The U.S. Food and Drug Administration today approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer. The test also can provide information about the patient’s risk for developing cervical cancer in the future.
A blood test performed before radical cystectomy in patients with urothelial cancer of the bladder could identify the presence of circulating tumor cells (CTCs), which are predictive of outcome, according to a new study.
- QRxPharma (ASX: QRX and OTCQX: QRXPY)
announced today that the United States Food and Drug Administration (FDA) Anesthetic and
Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo,
an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory
Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at